secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2022-10-06T23:59:59+00:00
Accession:  0000950170-22-019332
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen enters $12.5M upfront license deal with Boehringer Ingelheim for Fzd4 bispecific antibodies
--------------------------------------------------------------------------------

- Upfront payment of $12.5 million; eligible for up to $586.5M in development, regulatory, and commercial milestones.
- Royalties on net sales range from mid-single digit to low-double digit, subject to standard reductions.
- Boehringer Ingelheim leads development and commercialization of SZN-413 and other Fzd4 bispecifics for retinal diseases.
- 5-year exclusivity: Surrozen cannot develop Fzd4 bispecifics for eye diseases; BI restricted to eye diseases.
- Collaborative research period of one year (BI may extend 6 months) after which BI selects lead and back-up candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022019332/0000950170-22-019332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000095017022019332/srzn-20220930.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-019332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer